Somalogic Inc (SLGC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Somalogic Inc (SLGC) has a cash flow conversion efficiency ratio of -0.043x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.36 Million) by net assets ($496.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SLGC net asset quality score to measure how much of total assets are equity-financed.
Somalogic Inc - Cash Flow Conversion Efficiency Trend (2019–2022)
This chart illustrates how Somalogic Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore SLGC strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Somalogic Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Somalogic Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haleon PLC
LSE:HLN
|
0.032x |
|
Delcath Systems Inc
NASDAQ:DCTH
|
0.008x |
|
Nanyang Senba Optical and Electronic Co Ltd
SHE:300701
|
0.034x |
|
Duratec Ltd
AU:DUR
|
0.111x |
|
Shanghai Karon Eco-Valve Manufacturing Co. Ltd.
SHE:301151
|
0.167x |
|
Hyulim ROBOT Co.Ltd
KQ:090710
|
-0.070x |
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
-0.026x |
|
Tieling Newcity Investment Holding Ltd
SHE:000809
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Somalogic Inc (2019–2022)
The table below shows the annual cash flow conversion efficiency of Somalogic Inc from 2019 to 2022. For the full company profile with market capitalisation and key ratios, see Somalogic Inc (SLGC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $562.56 Million | $-100.67 Million | -0.179x | -196.23% |
| 2021-12-31 | $612.02 Million | $-36.97 Million | -0.060x | +60.37% |
| 2020-12-31 | $185.92 Million | $-28.34 Million | -0.152x | +93.84% |
| 2019-12-31 | $20.42 Million | $-50.54 Million | -2.475x | -- |
About Somalogic Inc
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in … Read more